SGLT2 Inhibitor
High-value in diabetes, heart failure, or kidney disease. Not a general-population longevity drug.
Approved Verified 27 August 2026
What it does
From glucose-lowering drugs to broad cardiovascular and renal protection in a decade. The outcomes data in heart failure and chronic kidney disease is striking; the role in otherwise-healthy adults is much narrower.
Blocks renal glucose reabsorption, causing urinary glucose excretion. The cardiovascular and renal benefits appear to extend beyond glucose lowering — via metabolic shifts, hemodynamic effects, and reduced renal tubular workload.
What the evidence shows
Overall evidence strength: High certainty
Who it's for, who should skip
Diabetes, heart failure, or chronic kidney disease. Not first-line for general longevity optimization in people without an indication.
Running it
- Form
- oral
- Dose
- daily
Measuring it
Retest HbA1c — Quarterly while titrating or not at goal, every 6 months once stable..
Safety
- euglycemic diabetic ketoacidosis
- genital mycotic infections, volume depletion
Access & cost
Prescription or clinician order — typically via cardiology, nephrology, or primary care.
Last reviewed 27 August 2026. Regulatory status verified 27 August 2026.